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by critical evaluation against traditional CEA (Cost Effective Analysis) via a scien-
tific process. Patient and Public Involvement (PPI) in HTA is associated with a low 
evidence base potentially limiting its value. Research presented at ISPOR 2012 by 
the same authors concluded a need to improve and standardize PAG input integra-
tion in HTA decision making. To investigate the way different forms of knowledge / 
experience are used by PAGs in NICE HTA for guideline development and new tech-
nology review. We will look at: 1) Influence of PAG structure, resource capability, 
internal process and the impact of PAG advisory board physician representatives 
on scientific validation of patient input in HTA participation, and 2) Part I results 
will inform further research into selection and ranking criteria of social derived 
data compared with CEA. An iterative PPI best practice approach will be followed. 
Selection criteria: Five UK PAG groups (Neurological, Autoimmune, Rare disease, 
Cardiovascular and Oncology) will be invited to participate. The NICE PPI Unit will 
nominate groups when needed. Inclusion criteria: 1) willingness to participate, 
2) prior involvement in guideline / new technology assessments; and 3) pres-
ence of medical advisory board. Research elements: Application of GRIPP criteria 
(Guidance Reporting Involvement Patient Public) to ensure a strong evidence base 
will guide development of an on-line survey and subsequent focus groups and 
interviews. The survey, designed for SAP review, will study: size of PAG, internal 
process for HTA involvement, previous HTA involvement, data submitted, PAG 
knowledge gaps and involvement of medical advisory board. Follow up by focus 
groups and interviews with PAG and advisory board members to identify insights/ 
themes.
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Juggling JuRisdictions: Methods foR conducting ModulaR 
systeMatic Reviews?
Thompson J., Hawkins N.
Oxford Outcomes Ltd., Oxford, UK
A crucial component of a systematic review is a clear description of the disposi-
tion of studies throughout the various steps of the review process (de-duplication, 
abstract review, full paper review and final inclusion). This is commonly achieved 
using a PRISMA diagram that shows the number of inclusions and exclusions at 
each stage of the review. This may be supplemented with details of the reasons for 
exclusion. To create the PRISMA diagram it is necessary to keep an on-going count of 
exclusions and inclusions throughout the review process. However, this can pose a 
challenge where the scope of a systematic review changes from the original specifi-
cation. This may happen where the set of licensed treatments or HTA requirements 
vary between jurisdictions or over time. In these cases, it may be time consuming to 
recreate the on-going counts of exclusions that correspond to the modified scope. 
We present a methodology for conducting a modular systematic review in which 
PRISMA diagrams and other descriptions of study disposition can be generated 
corresponding to any subsequent changes of scope. This is achieved by splitting 
the review into a set of ‘component-reviews’ defined by mutually exclusive treat-
ment search terms that comprise the full set of possible intersections between the 
individual treatments. Throughout the systematic review process separate counts of 
abstracts, papers and studies are maintained for each of these component-reviews. 
The results from the component-reviews can then be combined to reflect any final 
review scope (based on individual treatments). We will illustrate the methodology 
with an example review of the comparative efficacy of licenced thiazolidinedione’s 
(TZDs) versus placebo in patients with type 2 diabetes mellitus (T2DM) where there 
are two TZDs licensed in the USA (pioglitazone and rosiglitazone) but only one in 
Europe (pioglitazone).
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Objectives: Systematic reviews are often supplemented with the use of external 
experts to provide guidance on the nuances of the area. This can help add context 
if a review is used to support trial design or health economic model development. 
The ideal expert would have a deep understanding of the area and be well con-
nected to those individuals conducting trials. The aim of the current research 
was to assess whether social network analysis of coauthor networks could be 
used to rapidly and objectively identify individuals with the qualities desired in 
an external expert. MethOds: Publication lists from a recent systematic review 
of rheumatoid arthritis were used to produce a list of links between authors and 
publications. This was then imported into the Gephi program for social network 
analysis. Within Gephi, matrix multiplication was used to transform this net-
work into a coauthorship network. Eigenvector centrality was then used to infer 
the amount of access individual authors have to the research community as a 
whole. The use of eigenvector centrality as a measure of influence within the 
author network was then validated by correlating the centrality scores of a random 
sample of authors against independent ratings of desirability of those individu-
als’ expertise. Results: The coauthor network for rheumatoid arthritis, while 
not completely connected, showed a high degree of connectivity (mean degree: 
26, network diameter: 5). Eigenvector centrality allowed the identification of key 
experts, with the highest scoring experts each providing direct access to approxi-
mately half of the whole network. Eigenvector centrality measures were a reli-
able predictor of mean desirability scores from ten raters (F(1,9)= 20.35, p= 0.0015, 
R-squared= 0.69). cOnclusiOns: Social network analysis of coauthor networks 
provides an efficient and robust method for the identification of expertise, and 
can be used as part of the systematic review process.
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Objectives: Use of economic evaluation of health care technologies is intensively 
discussed in the government in Japan. In order to make evaluation results compa-
rable, standardized method of evaluation is required. We proposed an economic 
evaluation guideline in Japan. MethOds: We organized a research team for devel-
oping guideline. After reviewing guidelines in HTA agencies in the world and cur-
rent debate on issues, we investigated HTA reports and methodology of economic 
evaluation studies in several drugs, devices and procedures. Based on the review of 
these information, the research group discussed and proposed economic evalua-
tion guideline suitable for Japan. Results: Proposed guideline consist of 13 items: 
1) Objective; 2) Perspective of analysis; 3) Comparators; 4) Method of analysis; 
5) Time horizon; 6)Choice of outcomes; 7) Source of clinical data; 8) Costs; 9) 
Productivity loss; 10) Discounting; 11) Modeling; 12) Uncertainty; and 13) Budget 
impact analysis. Guideline sentences are classified into 3 levels, principal, recom-
mended, and optional. cOnclusiOn: This guideline is a proposal by a research 
team. However, it will be needed in the near future for using economic evalua-
tion of health care technologies. Proposed guideline should be tested by adopting 
individual studies.
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Objectives: Bayesian Network Meta-Analysis (NMA) models for binary data 
are well established and special precautions do not usually need to be taken in 
the case of zero cell counts. Furthermore, trials with zero cells in both arms are 
usually excluded from the analysis. However, in sparse networks with only one 
trial per comparison and zero cells in unique link studies, their inclusion may 
be mandatory. Zero frequencies may result in numerical instability and/or large 
variances. The objective of this study was to investigate the effect of different 
methods dealing with zero cells in sparse networks in Bayesian NMA. MethOds: 
A review was conducted to identify methods dealing with zero cells for binary 
outcomes in sparse networks in a Bayesian setting. The identified methods were 
applied to a sparse network with six treatments and one study per comparison. 
The outcome was grade 3+ Adverse Events and measured by Odds Ratio. A fixed 
effects model was fitted with binomial likelihood. The performance of the meth-
ods was assessed by the residual deviance and the Credible Intervals’ (CrI) width 
was compared. Results: We identified three methods: apply a continuity cor-
rection (a constant factor of 0.5 or the reciprocal of the opposite treatment size), 
use of informative priors on treatment effects and placing a distribution on the 
baseline model. We applied all methods and combinations of them. The model 
fit was adequate for all methods (residual deviance [10;12.3] for 12 datapoints). 
The use of different informative priors improved the variability estimates. CrI 
widths were reduced up to 15 times with respect to the original model with vague 
priors. cOnclusiOns: Although the debate on the inclusion of studies with zero 
events in NMA is still open, our research shows that methods are available to 
address this issue. However, no clear recommendations can be provided.
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Observational studies are frequently included in systematic reviews, especially in 
those disease areas where RCTs are limited. While there are very specific tools for 
and guidance on assessing the quality of RCTs, the assessment of observational 
studies is less standardized. OBJECTIVE: To understand and assess the different tools 
used to review the quality of observational studies and to make recommendations 
based on our evaluation. MethOds: First, a systematic review of literature from 
2005-present was conducted in Embase and Medline to determine the frequency 
of use of quality assessment for observational studies and the type of tools used to 
conduct the assessment. Second, we reviewed documentation from NHS guidance 
on quality assessment of non-randomized studies. Finally, we reviewed two years of 
approved HTA submissions to see what methods of assessment have been used for 
submissions. Results: A total of 1429 articles were screened. Compared to a similar 
study on older literature, our review found an increase in the use of quality assess-
ment for observational studies. However, we found that many studies continue to 
devise their own tool or adapt existing tools rather than use a tool in its entirety. 
Downs and Black, MOOSE, and STROBE were the most referenced tools, although 
STROBE was not originally intended for such use. Guidelines centered on “non-ran-
domized” studies were mixed and were not always found to be applicable to obser-
vational studies, but instead mostly to single-armed clinical trials. cOnclusiOns: 
There is still a need for guidance and standardization for observational studies 
assessment for use in systematic literature reviews. Although quality assessment 
of observational studies is still not standardized, there are a few methods becom-
ing more frequent in the literature but are difficult to compare across systematic 
literature reviews because they have often been adapted by each author.
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1Commutateur, Paris, France, 2University Claude Bernard Lyon 1, Lyon, France
Patient input in HTA pathways by the appropriate disease Patient Advocacy Group 
(PAG) uses principally humanistic and social studies as an evidence base followed 
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Health technology assessments (HTAs) rely on comparative evidence about new 
treatments and competing therapies, which are typically derived using indirect or 
mixed treatment comparisons (ITC/MTCs). These are not always feasible or appro-
priate, particularly in rapidly evolving therapeutic areas, like oncology. For instance, 
some comparisons may not be possible due to incomplete evidence networks; or, 
heterogeneity between studies due to differences in design or population may 
make an MTC inappropriate. There is, therefore, a need for alternative techniques, 
such as Simulated Treatment Comparisons (STCs). This technique is designed to 
derive comparisons between treatments after adjustment for differences between 
the populations of the two studies. This targeted comparison requires individual 
patient-level data (IPD) for at least one of the treatments (the index), and are appro-
priate when the trials used for the comparison are sufficiently comparable in design 
and methods, but differ in the profiles of their population in measured risk factors. 
The differences can be adjusted analytically using IPD via regression equations. This 
produces endpoint estimates for the index treatment that reflect the profile of the 
comparator population. These can then be contrasted with published results for 
the comparator to obtain a measure of difference between treatments. Since only 
measured risk factors can be included in the adjustment, the potential for residual 
confounding remains. Another potential bias is a possible “study effect” whereby 
other differences between studies distort the comparisons. This can be assessed 
using the reference groups of the trials, if these received the same treatment. STCs 
have been used in HTA submissions, and it is likely that its use and that of other 
alternative techniques will increase particularly in areas with rapid drug develop-
ment. In the presence of heterogeneity or incomplete evidence networks, STCs can 
provide comparative evidence where these may be otherwise deemed unavailable 
due to limitations of ITCs/MTCs.
PRM229
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canceR tReatMent Pathways
Langham J., Langham S., Weir S., Ralston S.
PHMR Associates, London, UK
RCTs remain the gold standard for evaluation of drug efficacy and safety. However, 
the only way of identifying treatment pathways and improving understanding of 
costs and outcomes at different stages of care is via longitudinal observational 
studies. Observational data from electronic health records (EHRs) are increas-
ingly being used to support pharmaco-epidemiological research. Coverage, data 
quality and validity of UK EHR databases such as the Clinical Practice Research 
Datalink (CPRD) have improved in recent years, and many papers confirm the 
validity of data in diagnoses such as cancer. Published data show that recording 
of cancer diagnosis and mortality in primary care electronic records is generally 
consistent with Cancer Registry (CR) data in England. The use of “read codes” in 
CPRD to identify an event (cancer diagnosis or referral to secondary care) and 
the possibility of anonymous linkage to secondary care databases (e.g. Hospital 
Episode Statistics [HES] for information about hospital management as an in- or 
out-patient, to other CR data, and accurate mortality tracking by the Office for 
National Statistics [ONS]) allows the data and diagnosis to be validated against 
multiple sources, as well as identifying treatment pathways in both secondary 
and primary care. There are some limitations, e.g. not all patients identified in GP 
practices via the CPRD are linked to other databases. Management data such as 
secondary care prescribing are difficult to access (not available in HES) but may 
be available from reviewing anonymized patient notes or by connecting to other 
datasets. For example, IMS Health links CPRD data with hospital pharmacy audit 
data and HES data. However these data have only become available recently, are 
expensive to access and currently patient population coverage is low. We will 
provide a detailed description of the possibilities for integrated database use to 
map treatment pathways for cancer patients.
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should theRe Be an oPtion to “unRefeR” nice single technology 
aPPRaisals: case study of aRiPiPRaZole foR BiPolaR i disoRdeR in 
adolescents
Uttley L., Kearns B., Stevenson M.
University of Sheffield, Sheffield, UK
Single technology appraisals (STAs) are a key component of the development of 
NICE technology appraisals guidance, but are a time and resource intensive process. 
Societal costs are incurred during STAs by holding the NICE Appraisal Committee, 
via payment to the evidence review group (ERG) and in the opportunity costs of 
other technologies which are not appraised. In addition, the drug manufacturer 
also incurs substantial costs in preparation of their submission and throughout 
the STA process. Recently aripiprazole, an atypical antipsychotic drug for the treat-
ment of manic episodes in adolescent bipolar I disorder, was subjected to an STA 
and received positive guidance. It was apparent to the ERG from the outset of the 
appraisal that the conclusion would be positive as: the drug had a small acquisi-
tion cost; was already in widespread use; would shortly be going generic; and had 
a profile similar to its comparators. As the budget impact over a 5-year period esti-
mated by the manufacturer was less than the payment received by the ERG, it was 
unlikely that the STA represented efficient use of resources. Given a fundamental 
role of NICE is in assessing cost-effectiveness, the option of un-referring STAs in 
rare circumstances has appeal. It is proposed that if certain criteria are met then 
it would be more cost-effective to not proceed with an STA. These include: small 
patient population, commonly used in current clinical practice, patent expiring in 
Systematic reviews aim to identify, select, synthesize and appraise all high qual-
ity research evidence relevant to a particular research question, and are widely 
accepted as the gold standard for providing the best evidence for use in decision 
making. They are essential, routine components of submission data packages 
for health technology assessments (HTAs) of products undergoing evaluation 
for reimbursement and market access. Additionally, systematic reviews are 
often the source for clinical evidence used in health economic modelling to 
evaluate cost-effectiveness. Thus, they represent a substantial investment of 
resources, and incorrect or incomplete reviews could invalidate the proposed 
clinical and economic value of a product set out in a health technology submis-
sion and result in unfavourable reimbursement decisions and/or delayed market 
access. There are a number of best practice criteria set down for systematic 
reviews; the most widely recognised being from the Cochrane group. However, 
when carrying out a systematic review for HTA purposes researchers should 
be aware of the additional requirements set out by each agency. The Cochrane, 
UK National Institute for Clinical Excellence (NICE) and Germany’s Institut für 
Qualität und Wirtschaftlichkeit im Gesundheitswesenis (IQWIG) methodologi-
cal guidelines for conducting and reporting systematic reviews were analysed 
and an ‘inclusive’ checklist of requirements was developed to ensure the sys-
tematic review and meta-analysis met the broad set of HTA requirements and 
minimise the risk of having to repeat the procedure or create the need for a 
HTA review group to carry out its own review, which could potentially lead to 
an unfavourable reimbursement decision or a restriction on use. An aware-
ness of specific HTA systematic review requirements can help optimise the 
preparation of a data package for HTA submission and hence maximise the 
chances of success.
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Objectives: The model aims to determine the optimal allocation of financial 
resources amongst various paediatric vaccines accounting for changes in budget 
and availability of new vaccines over time. This approach aims to inform decision 
makers who are seeking to extend their national immunisation programmes 
about the optimal mix of vaccines and sequence of their introduction, meanwhile 
accounting for their preferences in clinical and cost outcomes. MethOds: An 
MCD optimisation model was developed in Microsoft Excel that considered avail-
ability of new vaccines and budget changes over time, optimal mix of vaccines 
in previous years, budget investment time horizon, cumulative outcomes time 
horizon, maximal achievable vaccination coverage, specific target populations. 
The optimal mix of vaccines within an available portfolio was determined by 
manually programmed linear optimisation based on a defined objective func-
tion and budget constraints. The objective function includes maximisation of 
prevention of disease cases, GP visits, hospitalisations, deaths, and cost sav-
ings in disease management. A multi-criteria approach allows for redistributing 
weights across clinical and cost outcomes in the objective function. Vaccination 
against rotavirus, varicella, influenza and pneumococcal disease was evaluated, 
based on disease incidences and direct medical costs from Poland. Relative risk 
reductions induced by vaccination were based on randomised controlled trials 
and post-marketing surveillance data. Results: Dependent on the definition of 
objective function, the allocation of budget across a portfolio of vaccines resulted 
in different recommendations. If deaths-avoided was weighted at maximum, 
pneumococcal vaccine was ranked first, followed by rotavirus and influenza vac-
cination. If cost savings received the maximum preference, vaccination against 
influenza was ranked first, rotavirus second, pneumococcal third, and varicella 
fourth. The use of a weighted objective function resulted in different vaccines 
introduction sequences. cOnclusiOns: The use of an MCD optimisation model 
provides a tool to inform decision makers about the optimal allocation of finan-
cial resources over time.
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With the rapid pervasion of internet technologies, demand for making health 
economic evidence, such as mathematical models, accessible through the web 
increases. Long running computations such as Monte Carlo simulation can impair 
user experience because of longer waiting time. Our aim is to employ mathematical 
techniques to reduce the computation time of probabilistic cost effectiveness Monte 
Carlo models, thus increasing their acceptance when used on the web. We employ 
the variance reduction technique to reduce computation time while obtaining out-
comes with the same Monte Carlo error. The control variate approach is applied. 
It utilizes information about errors in estimates of known mean Net Monetary 
Benefit (NMB) quantities to reduce errors in estimation of the cost-effectiveness 
acceptability curve. The NMB mean value is calculated based on the deterministic 
counterpart of the model. The said technique has been applied to the published 
probabilistic decision tree-based Excel model for evaluating cost-effectiveness of 
breast cancer screening. In this model, different types of probability distributions 
can be chosen to model uncertainty of disease incidence, mortality rate and inter-
vention effectiveness. By applying the control variate approach we were able to 
achieve outcome with the same error while performing 50% less simulations as 
compared to the plain Monte Carlo method. Such performance improvement is yet 
another step towards increasing user acceptance of web based health economic 
models with Monte Carlo simulations.
